Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MARAVAI LIFESCIENCES HOLDINGS, INC.MRVI · Entity 4291 | Director · See Remarks | November 11, 2024 | November 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MARAVAI LIFESCIENCES HOLDINGS, INC.
Report date November 11, 2024 · Filed November 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectThrough The Hull Living Trust | 175,000 |
Reported balance
After 2024-11-11 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-11-11 · Purchase · Acquired 175,000 · Balance 175,000 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.52 to $5.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. |
| Class A Common StockSEC Table I · non-derivative | IndirectThrough Glossatori, LLC | 35,000 |
Reported balance
Holding disclosure · report date 2024-11-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 35,000 |
| Class A Common StockSEC Table I · non-derivative | Direct | 267,072 |
Reported balance
Holding disclosure · report date 2024-11-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 267,072 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.52 to $5.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ortho Clinical Diagnostics Holdings plc
Report date May 27, 2022 · Filed June 01, 2022
Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, $0.00001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 1
1 source rowRow 1 · 2022-05-27 · Disposition to issuer · Disposed 21,011 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated December 22, 2021, by and among Coronado Topco, Inc. ("Coronado Topco"), Laguna Merger Sub, Inc., Orca Holdco, Inc., Orca Holdco 2, Inc., Quidel Corporation and the Issuer, the Issuer became a wholly owned subsidiary of Coronado Topco upon consummation of the business combinations (the "Effective Time"). At the Effective Time: (a) each of the Issuer's ordinary shares was automatically converted into the right to receive (i) 0.1055 shares of common stock of Coronado Topco and (ii) $7.14 in cash; and (b) each restricted stock unit, whether vested or unvested, was converted into a Coronado Topco equity right of the same type and on the same terms and conditions as were applicable to the corresponding restricted stock unit immediately prior to the Effective Time, which right shall be settled in cash upon vesting. |
| Ordinary Shares, $0.00001 par valueSEC Table I · non-derivative | IndirectBy Hull Living Trust | 0 |
Reported balance
After 2022-05-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-05-27 · Disposition to issuer · Disposed 41,172 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated December 22, 2021, by and among Coronado Topco, Inc. ("Coronado Topco"), Laguna Merger Sub, Inc., Orca Holdco, Inc., Orca Holdco 2, Inc., Quidel Corporation and the Issuer, the Issuer became a wholly owned subsidiary of Coronado Topco upon consummation of the business combinations (the "Effective Time"). At the Effective Time: (a) each of the Issuer's ordinary shares was automatically converted into the right to receive (i) 0.1055 shares of common stock of Coronado Topco and (ii) $7.14 in cash; and (b) each restricted stock unit, whether vested or unvested, was converted into a Coronado Topco equity right of the same type and on the same terms and conditions as were applicable to the corresponding restricted stock unit immediately prior to the Effective Time, which right shall be settled in cash upon vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Business Combination Agreement, dated December 22, 2021, by and among Coronado Topco, Inc. ("Coronado Topco"), Laguna Merger Sub, Inc., Orca Holdco, Inc., Orca Holdco 2, Inc., Quidel Corporation and the Issuer, the Issuer became a wholly owned subsidiary of Coronado Topco upon consummation of the business combinations (the "Effective Time"). At the Effective Time: (a) each of the Issuer's ordinary shares was automatically converted into the right to receive (i) 0.1055 shares of common stock of Coronado Topco and (ii) $7.14 in cash; and (b) each restricted stock unit, whether vested or unvested, was converted into a Coronado Topco equity right of the same type and on the same terms and conditions as were applicable to the corresponding restricted stock unit immediately prior to the Effective Time, which right shall be settled in cash upon vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 11, 2024 Filed Nov 12, 2024 16:59 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | PurchaseClass A Common Stock | 175,000 | $5.64 | $987,000.00 |
DisclosureSEC source: 0001823239-24-000113 · wk-form4_1731448774.xml · nonDerivative · entry 1 HULL CARL · CIK 0001205465 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · Through The Hull Living Trust Disclosed balance after: 175,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.52 to $5.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 17:54 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 17,560 | $7.70 | $135,212.00 |
DisclosureSEC source: 0001823239-24-000034 · wk-form4_1710798854.xml · nonDerivative · entry 1 HULL CARL · CIK 0001205465 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,072 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 18:46 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 10,729 | $5.48 | $58,794.92 |
DisclosureSEC source: 0001823239-24-000023 · wk-form4_1708472789.xml · nonDerivative · entry 1 HULL CARL · CIK 0001205465 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,632 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 18:23 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 75,842 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-24-000008 · wk-form4_1705620203.xml · nonDerivative · entry 1 HULL CARL · CIK 0001205465 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,361 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in one-half (1/2) increments on each of January 15, 2025, and January 15, 2026, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:51 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantEmployee Stock Options (Right to Buy) · Derivative | 270,109 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001823239-23-000026 · wf-form4_167908626696366.xml · derivative · entry 3 HULL CARL · CIK 0001205465 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,109 Underlying: Class A Common Stock · 270,109 shares Expires 2033-03-15 F2 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on April 15, 2023 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:51 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 147,638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-23-000026 · wf-form4_167908626696366.xml · nonDerivative · entry 1 HULL CARL · CIK 0001205465 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,519 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of March 15, 2024, March 15, 2025, and March 15, 2026, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 16:33 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 9,719 | $15.23 | $148,020.37 |
DisclosureSEC source: 0001823239-23-000008 · wf-form4_167666958156029.xml · nonDerivative · entry 1 HULL CARL · CIK 0001205465 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,881 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:00 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | Disposition to issuerOrdinary Shares, $0.00001 par value | 41,172 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-033124 · doc4.xml · nonDerivative · entry 2 HULL CARL · CIK 0001205465 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Hull Living Trust Disclosed balance after: 0 F1 · price: Pursuant to the Business Combination Agreement, dated December 22, 2021, by and among Coronado Topco, Inc. ("Coronado Topco"), Laguna Merger Sub, Inc., Orca Holdco, Inc., Orca Holdco 2, Inc., Quidel Corporation and the Issuer, the Issuer became a wholly owned subsidiary of Coronado Topco upon consummation of the business combinations (the "Effective Time"). At the Effective Time: (a) each of the Issuer's ordinary shares was automatically converted into the right to receive (i) 0.1055 shares of common stock of Coronado Topco and (ii) $7.14 in cash; and (b) each restricted stock unit, whether vested or unvested, was converted into a Coronado Topco equity right of the same type and on the same terms and conditions as were applicable to the corresponding restricted stock unit immediately prior to the Effective Time, which right shall be settled in cash upon vesting. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:00 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | Disposition to issuerOrdinary Shares, $0.00001 par value | 21,011 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-033124 · doc4.xml · nonDerivative · entry 1 HULL CARL · CIK 0001205465 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Business Combination Agreement, dated December 22, 2021, by and among Coronado Topco, Inc. ("Coronado Topco"), Laguna Merger Sub, Inc., Orca Holdco, Inc., Orca Holdco 2, Inc., Quidel Corporation and the Issuer, the Issuer became a wholly owned subsidiary of Coronado Topco upon consummation of the business combinations (the "Effective Time"). At the Effective Time: (a) each of the Issuer's ordinary shares was automatically converted into the right to receive (i) 0.1055 shares of common stock of Coronado Topco and (ii) $7.14 in cash; and (b) each restricted stock unit, whether vested or unvested, was converted into a Coronado Topco equity right of the same type and on the same terms and conditions as were applicable to the corresponding restricted stock unit immediately prior to the Effective Time, which right shall be settled in cash upon vesting. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:00 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantEmployee Stock Options (Right to Buy) · Derivative | 151,200 | $0.00 Strike: $26.32 | $0.00 |
DisclosureSEC source: 0000899243-22-003415 · doc4.xml · derivative · entry 3 HULL CARL · CIK 0001205465 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,200 Underlying: Class A Common Stock · 151,200 shares Expires 2032-01-25 F2 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on March 15, 2022 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:00 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 81,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-003415 · doc4.xml · nonDerivative · entry 1 HULL CARL · CIK 0001205465 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,600 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of February 15, 2023, February 15, 2024, and February 15, 2025, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:00 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | GrantOrdinary Shares | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030376 · doc4.xml · nonDerivative · entry 1 HULL CARL · CIK 0001205465 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,011 F1 · shares: Represents restricted stock units, which vest in eight equal quarterly installments beginning on June 30, 2021. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 16:34 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | PurchaseClass A Common Stock | 35,000 | $26.94 | $942,900.00 |
DisclosureSEC source: 0000899243-20-032306 · doc4.xml · nonDerivative · entry 1 HULL CARL · CIK 0001205465 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Through Glossatori, LLC Disclosed balance after: 35,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.81 to $27.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 17:33 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantEmployee Stock Options (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0000899243-20-031948 · doc4.xml · derivative · entry 1 HULL CARL · CIK 0001205465 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Class A Common Stock · 60,000 shares Expires 2030-11-19 F1 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan in connection with the pricing of the Issuer's initial public offering. These options will vest 25% on November 19, 2021 and in equal monthly installments thereafter over the next three years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.